ESMO Congress Round-Up With Dr. Evan Yu: LITESPARK-005

By Evan Yu, MD - Last Updated: November 2, 2023

In the third part of this ESMO Congress round-up video series, Evan Yu, MD, of the Fred Hutchinson Cancer Center, explains the momentum for belzutifan in renal cell carcinoma to date.

He also expounds on the large takeaways to be gleaned from the LITESPARK-005 trial.

View Dr. Yu’s further thoughts on EV-302 and CheckMate 901, as well as PSMAfore.

PSMAfore: Control Arm and Sequencing Considerations

Oliver Sartor, MDRLT | December 4, 2023

Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.

PSMAfore: Methodology, Nuances, and Implications

Oliver Sartor, MDRLT | December 4, 2023

Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.

Biomarkers of TRAEs in Patients With Advanced UC Treated With EV: Analysis of the UNITE Study

Amanda Nizam, MDAdvanced Urothelial Carcinoma | November 20, 2023

Dr. Nizam provides an overview of her recent research on biomarkers of TRAEs associated with EV for aUC.

ESMO Congress Round-Up With Dr. Evan Yu: PSMAfore

Evan Yu, MDESMO 2023 | November 2, 2023

Dr. Evan Yu gives a background on the successes of Lu-177 PSMA-617 and how the PSMAfore data add to our understanding.

EV-103 Cohort L: Investigating Enfortumab Vedotin as SOC for Cisplatin-Ineligible MIBC

Emily MenendezESMO 2023 | October 31, 2023

Enfortumab vedotin shows promising activity and tolerability in cisplatin-ineligible patients with MIBC.

ESMO Congress Round-Up With Dr. Evan Yu: LITESPARK-005

Related Posts